Abstract submission is now closed, but late submissions can be considered for poster presentation. Please contact the conference manager at FPMBCW2022@confedent.fi for late submission.
Abstracts selected for oral presentations:
- Sofia Aakko (Faron Pharmaceuticals, Finland ): “Ex vivo immune activation with the macrophage-targeting immunotherapy, anti-Clever-1 antibody bexmarilimab, in acute myeloid leukemia and myelodysplastic syndrome”
- Katie Dunphy (Maynooth University,Ireland): “Understanding extramedullary multiple myeloma using quantitative proteomics”
- Arjen Gebraad (Tampere University, Finland): ”Bone Marrow and Adipose Tissue Stem/Stromal Cells as Pericytes Generate Distinct Vascular Phenotypes”
- Merja Heinäniemi (University of Eastern Finland, Finland): ”Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia”
- Petra Nygren (University Of Helsinki, Finland): “High-throughput evaluation of the potential of cancer drugs to enhance natural killer cell cytotoxicity in hematological malignancies”
- Joseph Saad (Institute for Molecular Medicine Finland - FIMM, Helsinki Institute of Life Science - HiLIFE, University of Helsinki): ”Monosomy 7 and del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia”
- Imre Västrik (Institute for Molecular Medicine Finland – FIMM, Finland): ”Functional precision medicine data platform”
- Alexander Waclawiczek (German Cancer Research Center, Germany): ”Flow cytometry-based combinatorial BCL-2 family expression in Acute Myeloid Leukemia Stem Cells predicts clinical response to Venetoclax and other BH3-mimetics”
Abstracts selected for poster presentation:
- Sadiksha Adhikari (University of Helsinki, Finland): “CYLD as a biomarker for resistance to immunomodulatory treatments in multiple myeloma”
- Andres Blanco (University of Pennsylvania, United States): “Targeting epigenetic regulators to override cellular identity programs and induce therapeutic differentiation in MLL-rearranged acute myeloid leukemia”
- Kieran Brennan (University College Dublin, Ireland): “Multiple Myeloma Plasma Extracellular Vesicles from patients treated with Daratumumab show elevated levels of complement inhibitory proteins CD55 and CD59”
- Anthony Brown (St. Jude Children's Research Hospital, United States): “Development of an Imaging-based Platform for Ex Vivo Drug Sensitivity Testing of Acute Lymphoblastic Leukemia”
- Anna Dolnik (Charité University Medicine Berlin, Germany): “Combined CRISPR-Cas9 targeted enrichment and whole genome sequencing profiling allows real time stratification of acute myeloid leukemia (AML)”
- Hanna Duàn (University of Helsinki, Finland): “Ex vivo modeling of NK cell immunotherapy response in acute myeloid leukemia using single-cell transcriptomics”
- Kat Ginda-Mäkelä (Applied Cells Inc., United States): “A New Approach for High Recovery and Purity Isolation of Plasma Cells from Whole Blood and Bone Marrow”
- Konstantin Ivanov (University of Eastern Finland, Finland): “Deep variational autoencoder modeling of multimodal single-cell data resolves molecular fingerprints of pre-leukemic states”
- Niveditha Umesh Katyayini (Oslo universitetssykehus - Norwegian Radium Hospital, Norway): “The LD-VenEx phase II clinical trial: An ex vivo flow cytometry based-drug screening of AML patient samples”
- Elmira Khabusheva (University of Helsinki, Finland): “HDAC inhibitors resensitize AML cells to the BCL-2 and BCL-2/BCL-xL inhibitors venetoclax and navitoclax”
- Olga Krali (Uppsala University, Sweden): “A multiscale machine learning approach for molecular subtype determination of pediatric acute lymphoblastic leukemia”
- Romika Kumari (Institute for Molecular Medicine Finland, Finland): “CD8+ effector and memory T-cells are associated with venetoclax sensitivity in acute myeloid leukemia”
- Adriana Ladungova (CEITEC, Masaryk University, Czech Republic): “Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing”
- Mari Lahnalampi (University of Eastern Finland, Finland): “Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure”
- Timofey Lebedev (Engelhardt Institute of Molecular Biology, Russian Federation): “Prediction of novel drug targets for pediatric acute leukemias by combining transcriptome, gene fitness and drug action data”
- Alina Malyutina (University of Helsinki, Finland): “Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma”
- Mehdi Mirzaie (University of Helsinki, Finland): “Drug combinations for acute myeloid leukemia”
- Laura Oksa (Tampere University, Finland): “Genomic Determinants of Therapy Response in Etv6-Runx1 Leukemia”
- Jani Saarela (University of Helsinki / FIMM,Finland): “Ex vivo Drug Sensitivity Testing of Primary Cells for Functional Precision Medicine”
- Philipp Sergeev (FIMM, Finland): “Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma”
- Rebecca Sheridan (University College Dublin, Ireland): “Analysis of Multiple Myeloma Extracellular Vesicles uptake by bone marrow microenvironment cells and characterisation downstream cytokine release”
- Ankita Srivastava (University of Helsinki, Finland): “Deciphering plasma cell heterogeneity and tumor microenvironment in light-chain amyloidosis using single-cell RNA-sequencing"
- Nona Struyf (Karolinska Institute, Sweden): “Comparison of data from fresh and frozen AML samples for functional drug testing”
- Silja Tammi (Finnish Red Cross Blood Service , Finland): “Finnish Hematology Registry and Biobank (FHRB): a national population-based comprehensive biobank resource for hematological research”
- Sylvain Tollis (University of Eastern Finland, Finland): “Towards a mechanistic understanding of cell-cycle rewiring during hematopoietic differentiation: insight from single cell transcriptomics and quantitative live-cell imaging”
- Dimitrios Tsallos (Institute For Molecular Medicine Finland – FIMM,Finland): “Resistance to the proteasome inhibitor bortezomib is associated with a gain in sensitivity to BCL-xL inhibition in multiple myeloma”
- Tania Vu (Knight Cancer Institute, Oregon Health and Science University, United States): "Evaluating Immune-Oncology-Small Molecule Drug Responsesin Individual AML Patients by Single Cell Functional Precision Imaging"